17,261 trials
Parkinson's Disease
Primary: Varenicline Occupancy of alpha4beta2* Nicotinic Acetylcholine Receptors — 67.0; 67.9; 65.7; 70.6 percentage of VCN-alpha4beta2* nAChRs
Refractory Chronic Cough
Primary: Cough Reflex Sensitivity to Capsaicin Measured by Maximal Cough Response (Emax) — 4.14; 4.14; 7.57; 3.66 Emax (Explosive coughs/15 sec) — p=< 0.0001
Heart Failure
Primary: Change From Baseline to Week 12 in Log-transformed N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) — -0.098; -0.047; 0.071; 0.057 log-transformed picograms per…
Sports Concussion
Primary: Liver Function Testing (Aspartate Transaminase [AST]/Alanine Transaminase [ALT] Ratios) to Screen for Adverse Events. — 1.57; 1.24 AST/ALT ratio
Glabellar Frown Lines
Primary: Number of Composite Responders at Month 1 — 64; 71; 72; 77 Participants
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) · Carnitine Palmitoyltransferase (CPT II) Deficiency · Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
Primary: Change From Baseline in Time Adjusted-Area Under the Curve (AUC/Time) for Workload During Cycle Ergometry at Week 24 — 423.594 watts — p=0.1518
Medullary Thyroid Cancer (MTC)
Primary: Clinical Response — 0; 0 Participants
Acute Myeloid Leukemia
Primary: Best Response Rate — 26 Participants
Human Immunodeficiency Virus (HIV)
Primary: Primary Outcome Measure — 1; 2 Participants
Infections, Meningococcal
Primary: Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup A for Each Vaccine Group, and Between-group Ratios…
Clostridium Infections
Primary: Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) — 7; 25 Participants
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c to Week 26 — -0.663; -1.517; -1.618; -1.562 percentage of HbA1c — p=< 0.0001
Adult Alveolar Soft Part Sarcoma · Adult Angiosarcoma · Adult Desmoplastic Small Round Cell Tumor
Primary: Progression-free Survival (PFS) — 4.5; 1.6; 8.9; 1.5 months — p=0.017
Stable Schizophrenia
Primary: Change From Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Second Testing After TAK-041 Administration — 29.72; 27.35; 27.89…